Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus

Aim. To study the influence of combined therapy on carbohydrate and lipid metabolism and neurological status in patients with type 2 diabetes mellitus (DM) and diabetic neuropathy (DN).Materials and methods. Seventy-eight patients with type 2 DM and DN were examined. The first group included 58 pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inessa I. Dubinina, Svetlana V. Berstneva, Vadim V. Baranov, Larisa V. Azimkova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2016
Materias:	type 2 diabetes mellitus diabetic neuropathy antioxidant therapy Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/88db23cd721944f3b9f700e4fa95c11e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:88db23cd721944f3b9f700e4fa95c11e
record_format	dspace
spelling	oai:doaj.org-article:88db23cd721944f3b9f700e4fa95c11e2021-11-14T09:00:20ZEfficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus2072-03512072-037810.14341/DM7637https://doaj.org/article/88db23cd721944f3b9f700e4fa95c11e2016-11-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7637https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To study the influence of combined therapy on carbohydrate and lipid metabolism and neurological status in patients with type 2 diabetes mellitus (DM) and diabetic neuropathy (DN).Materials and methods. Seventy-eight patients with type 2 DM and DN were examined. The first group included 58 patients who were prescribed alpha-lipoic acid drugs (Octolipen, Thioctacid, Thiogamma and Berlithion) at 600 mg/day dropwise as antihyperglycemic therapy and B group vitamins (combilipen and milgamma) at 2 mL/day with further oral intake of octolipen, thioctacid HR and berlithion at 600 mg/day and liposoluble formulations, such as combilipen tabs, milgamma compositum or benfogamma, for 12 weeks. The second group included 20 patients with type 2 DM and DN who received antihyperglycemic therapy. All of the patients were comparable in age, DM status, DN duration, body mass index and concomitant diseases. The third group (control) included 18 healthy individuals. The efficacy of therapy was determined by assessing HbA1c dynamics, glycaemic control, lipid spectrum and sensorimotor symptoms under the TSS and NIS-LL scales; measuring pain levels with the McGill Pain Questionnaire and visual analogue scale (VAS); and performing stimulation electroneuromyography of n. tibialis and n. peroneus to analyse M-wave characteristics, nerve conduction velocity (NCV) and residual latency (RL). All analyses were performed before the administration of combined therapy and at the completion of the 12-week treatment.Results. Comparative analysis of the combined therapy of patients with type 2 DM and DN demonstrated an improvement in positive neurological symptomatology according to the TSS scale and reduced negative symptoms according to the NIS-LL scales as well as reductions in neuropathy symptoms according to the McGill Pain Questionnaire and trends toward M-wave growth with reduced RL and increased NCV. Furthermore, individual-targeted glycaemic control (HbA1c < 7.5%) was achieved of 78% with consistent reduction in the atherogenicity index. Correlation analysis determined an average direct link between the HbA1c level and negative neurologic manifestations on the NIS-LL scale (r = 0.42, p = 0.027) and an inverse link between the McGill Pain Questionnaire score and NCV (r = -0.36, p = 0.019).Conclusions. The complex diagnostics of neurological changes (TSS, NIS-LL, McGill and VAS scales) allows the assessment of the severity of distal DN after combined therapy with alpha-lipoic acid drugs (600 mg) and liposoluble forms of B group vitamins. These methods are also recommended for use in outpatient settings for the early detection and prevention of the diabetic foot development.Inessa I. DubininaSvetlana V. BerstnevaVadim V. BaranovLarisa V. AzimkovaEndocrinology Research Centrearticletype 2 diabetes mellitusdiabetic neuropathyantioxidant therapyNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 19, Iss 4, Pp 315-321 (2016)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus diabetic neuropathy antioxidant therapy Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus diabetic neuropathy antioxidant therapy Nutritional diseases. Deficiency diseases RC620-627 Inessa I. Dubinina Svetlana V. Berstneva Vadim V. Baranov Larisa V. Azimkova Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
description	Aim. To study the influence of combined therapy on carbohydrate and lipid metabolism and neurological status in patients with type 2 diabetes mellitus (DM) and diabetic neuropathy (DN).Materials and methods. Seventy-eight patients with type 2 DM and DN were examined. The first group included 58 patients who were prescribed alpha-lipoic acid drugs (Octolipen, Thioctacid, Thiogamma and Berlithion) at 600 mg/day dropwise as antihyperglycemic therapy and B group vitamins (combilipen and milgamma) at 2 mL/day with further oral intake of octolipen, thioctacid HR and berlithion at 600 mg/day and liposoluble formulations, such as combilipen tabs, milgamma compositum or benfogamma, for 12 weeks. The second group included 20 patients with type 2 DM and DN who received antihyperglycemic therapy. All of the patients were comparable in age, DM status, DN duration, body mass index and concomitant diseases. The third group (control) included 18 healthy individuals. The efficacy of therapy was determined by assessing HbA1c dynamics, glycaemic control, lipid spectrum and sensorimotor symptoms under the TSS and NIS-LL scales; measuring pain levels with the McGill Pain Questionnaire and visual analogue scale (VAS); and performing stimulation electroneuromyography of n. tibialis and n. peroneus to analyse M-wave characteristics, nerve conduction velocity (NCV) and residual latency (RL). All analyses were performed before the administration of combined therapy and at the completion of the 12-week treatment.Results. Comparative analysis of the combined therapy of patients with type 2 DM and DN demonstrated an improvement in positive neurological symptomatology according to the TSS scale and reduced negative symptoms according to the NIS-LL scales as well as reductions in neuropathy symptoms according to the McGill Pain Questionnaire and trends toward M-wave growth with reduced RL and increased NCV. Furthermore, individual-targeted glycaemic control (HbA1c < 7.5%) was achieved of 78% with consistent reduction in the atherogenicity index. Correlation analysis determined an average direct link between the HbA1c level and negative neurologic manifestations on the NIS-LL scale (r = 0.42, p = 0.027) and an inverse link between the McGill Pain Questionnaire score and NCV (r = -0.36, p = 0.019).Conclusions. The complex diagnostics of neurological changes (TSS, NIS-LL, McGill and VAS scales) allows the assessment of the severity of distal DN after combined therapy with alpha-lipoic acid drugs (600 mg) and liposoluble forms of B group vitamins. These methods are also recommended for use in outpatient settings for the early detection and prevention of the diabetic foot development.
format	article
author	Inessa I. Dubinina Svetlana V. Berstneva Vadim V. Baranov Larisa V. Azimkova
author_facet	Inessa I. Dubinina Svetlana V. Berstneva Vadim V. Baranov Larisa V. Azimkova
author_sort	Inessa I. Dubinina
title	Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
title_short	Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
title_full	Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
title_fullStr	Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
title_full_unstemmed	Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
title_sort	efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2016
url	https://doaj.org/article/88db23cd721944f3b9f700e4fa95c11e
work_keys_str_mv	AT inessaidubinina efficacyofcomplexpathogenictherapyofdiabeticdistalneuropathyinpatientswithtype2diabetesmellitus AT svetlanavberstneva efficacyofcomplexpathogenictherapyofdiabeticdistalneuropathyinpatientswithtype2diabetesmellitus AT vadimvbaranov efficacyofcomplexpathogenictherapyofdiabeticdistalneuropathyinpatientswithtype2diabetesmellitus AT larisavazimkova efficacyofcomplexpathogenictherapyofdiabeticdistalneuropathyinpatientswithtype2diabetesmellitus
_version_	1718429542439190528

Efficacy of complex pathogenic therapy of diabetic distal neuropathy in patients with type 2 diabetes mellitus

Ejemplares similares